NF1 and glioblastoma: We performed genome-wide CRISPRi screens in 2 cell models of NF1-mutant glioblastoma: NF1-mutant human GBM43 cells and NrasG12V mutant mouse SB28 cells using a selumetinib dose of 1 μM, which approximates the selumetinib IC50 in both GBM43 and SB28 cells, and terminating each screen at an average of 5 population doublings across selumetinib replicates for each cell line (Figure 4A and Supplemental Tables 11 and 12).